pegcetacoplan
pegcetacoplan: sourced relationships with 1 company · 12 clinical trials tracked.
pegcetacoplan evidence translation
What we can confirm
12 tracked trials
What it means
What to watch
Prepared research question
How could pegcetacoplan → APLS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (4)
| Company | Dated record stage |
|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | Approved |
| Apellis Pharmaceuticals, Inc. (APLS) | Phase 3 |
| Apellis Pharmaceuticals, Inc. (APLS) Geographic atrophy secondary to age-related macular degenera… | Approved |
| Apellis Pharmaceuticals, Inc. (APLS) | Phase 3 |
Clinical Trial Registry Records (12)showing 10 most recent
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With Pegcetacoplan
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Primary endpoint: Time to freedom from dialysis through Day 90
Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Primary endpoint: Number of Participants Experiencing Adverse Events
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Primary endpoint: Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US prescribing information
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Primary endpoint: Proportion of participants with a reduction in urine protein-to-creatinine ratio (uPCR) of at least 50% from the pretreatment value over time.
An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients With Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Primary endpoint: Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau)
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Primary endpoint: Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN
Primary endpoint: Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Primary endpoint: Incidence and severity of ocular and systemic adverse events
An Open Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria
Primary endpoint: Pegcetacoplan serum concentrations over the course of the 16-week treatment period
Frequently asked questions
Which companies have sourced relationships with pegcetacoplan?
pegcetacoplan has dated SEC/FDA relationship records for Apellis Pharmaceuticals, Inc..
How many clinical trials involve pegcetacoplan?
BioSniper tracks 12 clinical trials involving pegcetacoplan.